SK bioscience announced on the 7th that its operating loss for the first quarter of this year amounted to 15.1 billion won on a consolidated basis. This marks a reduction in the deficit compared to the operating loss of 28.1 billion won in the first quarter of the previous year. Revenue for the first quarter reached 154.6 billion won, a 594% increase from the same period last year. The net loss decreased to 4.1 billion won.
The performance of IDT Biologika, acquired last October, has been reflected, leading to increased sales and improved results due to the strong sales of the self-developed vaccine. IDT transitioned to a surplus in the fourth quarter of last year and maintained profitability in the first quarter of this year. The goal is to surpass 410 billion won in annual sales.
The company explained that it is expanding exports of its influenza vaccine "Skycellflu" to the Southern Hemisphere and extending the supply period of its chickenpox vaccine "Skyvaricella" to the Latin American market until 2027, achieving global market entry for its self-developed vaccines. It also noted that strengthened collaborations, including a co-marketing agreement with the global pharmaceutical company Sanofi for the respiratory syncytial virus (RSV) preventive antibody injection, are contributing to its performance.
SK bioscience stated, "We plan to continue our growth through sustained research and development investment and strategic partnerships, while rapidly improving our performance through IDT's stable growth and the exploration of new markets for our self-developed vaccines."